Silo Pharma, Inc.
Silo Pharma, Inc. (SILO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
silo · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Silo Pharma, Inc. (SILO) measures how much investors pay for each dollar of the company's trailing earnings. SILO's current PE ratio of N/A is calculated by dividing its stock price of $6.14 by its TTM earnings per share of -$5.30.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2010 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%49.2x
MedianQ3 · 75%345.0x
Max
At N/A, SILO's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Silo Pharma, Inc.You SILO | $6M | N/A | — | -$5.30 |
 Biodexa Pharmaceuticals Plc BDRX | $1M | N/A | — | -$113.82 |
 Can-Fite BioPharma Ltd. CANF | $2M | N/A | — | -$12.02 |
 Clearmind Medicine Inc. CMND | $4M | N/A | — | -$3.03 |
 CNS Pharmaceuticals, Inc. CNSP | $3M | N/A | — | -$35.75 |
 GRI Bio, Inc. GRI | $0M | N/A | — | -$121.80 |
 InMed Pharmaceuticals Inc. INM | $3M | N/A | — | -$8.36 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-7.57 | — | |
2024-12-31 FY2024 | — | $-17.90 | — | |
2023-12-31 FY2023 | — | $-18.02 | — | |
2022-12-31 FY2022 | — | $-25.67 | — | |
2021-12-31 FY2021 | 3.48x | $30.86 | — | |
2020-12-31 FY2020 | — | $-34.54 | — | |
2019-12-31 FY2019 | — | $-18.05 | — | |
2018-12-31 FY2018 | — | $-14.81 | — | |
2017-12-31 FY2017 | 49.16x | $5.34 | — | |
2016-12-31 FY2016 | — | $-16.63 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Silo Pharma, Inc. (SILO) measures how much investors pay for each dollar of the company's trailing earnings. SILO's current PE ratio of N/A is calculated by dividing its stock price of $6.14 by its TTM earnings per share of -$5.30.
Frequently asked questions
SILO pe ratio · 6 questionsSILO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $6.14 and TTM EPS of -$5.30. Data sourced from Financial Modeling Prep via SILO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Silo Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08